Roche and I-Mab form collaboration to study Tecentriq/TJD5 combination
I-Mab Biopharma agreed to combine its anti-CD73 bispecific antibody TJD5 with Roche’s PD-L1 antagonist Tecentriq (atezolizumab) in a Phase I trial of patients with advanced or metastatic solid tumors who are refractory to or intolerant to all available therapy. The partners will share rights generated by the alliance.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com